OVARIAN CANCER TREATMENT: THERAPEUTIC APPROACHES AND RECENT ADVANCES
Keywords:
Ovarian Cancer, PARP Inhibitors, Immunotherapy, Precision Medicine, Radiomics, Artificial Intelligence, ChemotherapyAbstract
Ovarian cancer, particularly epithelial carcinoma, is a lethal and challenging neoplasm, frequently diagnosed at advanced stages and with high recurrence rates. This narrative review analyzes contemporary therapeutic strategies, highlighting the transition from standard chemotherapy (platinum and taxanes) to precision medicine. The identification of biomarkers such as BRCA mutations and Homologous Recombination Deficiency (HRD) has validated the use of PARP inhibitors (e.g., olaparib), which demonstrate significant benefits in overall survival. The emerging role of combined immunotherapy (checkpoint inhibitors associated with antiangiogenics) to modulate the immunosuppressive tumor microenvironment is discussed. Furthermore, the review addresses the potential of artificial intelligence and radiomics as non-invasive tools to predict therapeutic response and platinum sensitivity, aiming to overcome resistance and personalize treatment.
